INCRUSE ELLIPTA (umeclidinium) Patient Assistance Program
Don’t let the cost of Incruse Ellipta disrupt your COPD treatment. GSK’s patient assistance program provides Incruse free of charge to eligible patients — and GSK now caps out-of-pocket costs at $35 per inhaler for most others. We manage your entire enrollment for a flat $69.95 per month.
- Clear & Transparent Pricing — Applying To GSK Directly Is Always Free
- Paperwork, Documentation & Doctor-Coordination Handled For You
- Comprehensive Support: From Application to Entire Journey.
- $35-Cap And Direct-Purchase Guidance — Incruse Gained Two New Cost Routes Since 2025
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Incruse Ellipta (Umeclidinium) Is A Once-Daily Maintenance Inhaler For COPD — A Long-Acting Muscarinic Antagonist (LAMA) In The Same Breath-Activated Ellipta Device As Anoro And Trelegy. It Is Not A Rescue Inhaler.
- List Price Runs About $354 Per 30-Day Inhaler — But Since 2025, GSK Caps Out-Of-Pocket Costs For Its Entire Inhaler Portfolio, Including Incruse, At $35 Per Month For Commercially Insured And Cash-Pay Patients, And Since March 2026 GSK Sells Incruse Direct To Consumers At $159.20 — 55% Off List.
- The GSK Patient Assistance Program Provides Incruse Free To Patients With Household Income Up To $47,880 (One Person) / $99,000 (Family Of Four) — Including Medicare Part D Enrollees Who Have Spent $600 On Prescriptions This Calendar Year — With 90-Day Supplies Shipped To Your Home.
- No Generic Is On Pharmacy Shelves (An Authorized Generic Is FDA-Listed But Not Yet Marketed; The Key Patent Runs To Late 2027) — And While Incruse Itself Isn’t In Medicare Price Negotiation, Its Siblings Are: Trelegy And Breo Get Negotiated Prices In 2027, Anoro In 2028.
What Is Incruse Ellipta Prescription Assistance Program?
The Incruse Ellipta Patient Assistance Program is run through the GSK Patient Access Programs Foundation and provides Incruse at no medication cost to qualifying patients: U.S. residents with household income up to roughly 300% of the Federal Poverty Level ($47,880 for one person, $64,920 for two, $99,000 for a family of four — higher in Alaska and Hawaii), covering both the uninsured and Medicare Part D enrollees who have paid at least $600 out of pocket for prescriptions in the current calendar year. Approved patients receive 90-day supplies shipped to their home. Applying directly (1-866-728-4368, Mon–Fri 8 AM–8 PM ET) is always free. Incruse’s cost landscape now has four overlapping routes — free drug, the $35-per-inhaler cap, GSK’s new $159 direct-purchase price, and the standard coupon — and each has different eligibility fine print, especially around Medicare. For a flat $69.95 per month, our Patient Advocates check every route and enroll you in the one that costs you least, then keep it renewed.
Pharmacy Price Comparison
- Without assistance, Incruse Ellipta costs roughly $370–$470 per inhaler. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$450.00 | Save ~$380/inhaler |
| CVS Pharmacy | ~$470.00 | Save ~$400/inhaler |
| Walmart | ~$390.00 | Save ~$320/inhaler |
| Costco | ~$375.00 | Save ~$305/inhaler |
| Kroger | ~$385.00 | Save ~$315/inhaler |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Incruse Ellipta Prescription Program?
The Patient Assistance Program is free to apply for and provides Incruse Ellipta at no medication cost if approved. But the process involves detailed applications, prescriber coordination, prior-authorization documentation, and ongoing renewal management. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Incruse Ellipta:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $370–$470 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
The GSK Patient Assistance Program publishes clear eligibility rules for free Incruse. You will generally qualify if all of the following are true — and if your situation doesn’t fit neatly, contact AffordMyPrescriptions so we can review your case and determine if you qualify for Incruse assistance:
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Incruse Ellipta Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured — Or On Medicare Part D And Have Paid At Least $600 For Prescriptions This Calendar Year
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Incruse Ellipta:
Incruse Ellipta (umeclidinium) is a long-acting muscarinic antagonist (LAMA) — a once-daily bronchodilator that keeps COPD airways open by blocking the nerve signals that trigger airway-muscle tightening.
How Incruse Works:
In COPD, overactive cholinergic nerve signaling keeps airway muscles chronically constricted. Umeclidinium blocks the muscarinic receptors those signals use, relaxing the airways for a full 24 hours per dose. As a single-agent LAMA, Incruse is often the starting maintenance inhaler in COPD — with the practical advantage that stepping up later (to Anoro, which adds a LABA, or Trelegy, which adds a LABA and steroid) keeps you in the same Ellipta device family, so your inhaler technique carries over.
Form and Use:
One inhalation, once daily, at the same time each day, from the breath-activated Ellipta dry-powder device — each lasts 30 days. Incruse is maintenance-only: it will not relieve sudden breathlessness, and every patient should carry a separate rescue inhaler. In COPD, the cost that matters is annual, not per-fill — 12 inhalers a year, every year — which is why a renewable program beats a one-off discount every time.
Generic Availability:
No generic umeclidinium is on pharmacy shelves. An authorized generic (Prasco) is FDA-listed but not commercially available yet, and the key patent runs to December 2027 — so generic relief is plausible within a couple of years but not here today. Meanwhile the pricing pressure is arriving another way: Trelegy and Breo get Medicare-negotiated prices in 2027 and Anoro in 2028, and GSK has already responded with the $35 cap and direct-purchase pricing that benefit Incruse users now.
Warnings:
Incruse should not be used for acute bronchospasm, and patients with severe milk-protein allergy should avoid it (lactose carrier). Tell your prescriber about narrow-angle glaucoma, urinary retention, or prostate problems — anticholinergics can worsen all three — and about every other inhaler you use, since duplicating LAMA drugs (for example, Incruse plus Anoro or Trelegy, which already contain umeclidinium) is a common and avoidable error. Report eye pain, vision halos, difficulty urinating, or paradoxical worsening of breathing promptly.
FAQ (Frequently Asked Questions)
How Much Does Incruse Ellipta Cost Without Insurance?
List price is about $354 per 30-day inhaler — roughly $4,250 per year. But uninsured patients have three better routes: the GSK Patient Assistance Program (free if income-eligible), the $35-per-inhaler coupon cap (open to cash payers), and GSK’s direct-purchase price of $159.20 per month. Our $69.95 monthly fee covers finding and enrolling in the cheapest one for you.
What Is GSK’s $35 Inhaler Cap?
Since January 2025, GSK caps out-of-pocket costs for its entire U.S. asthma and COPD inhaler portfolio — Incruse included — at $35 per month for eligible commercially insured and cash-pay patients, through the GSK copay program (up to 12 uses per year). Medicare and Medicaid patients are excluded from the coupon, but have their own protections below.
Does Medicare Cover Incruse?
Yes — under Part D, with the $2,100 annual out-of-pocket cap (2026) limiting total drug spending. And the GSK Patient Assistance Program accepts Part D enrollees who have paid $600 out of pocket for prescriptions this calendar year — once you cross that threshold, free 90-day home shipments can replace pharmacy fills entirely for the rest of the year.
Is There A Generic For Incruse?
Not on shelves — an authorized generic is FDA-listed but not marketed, and the main patent runs to late 2027. Ask your pharmacist to check availability at fill time; until then, the programs above are the affordability route.
What’s The Difference Between Incruse, Anoro, And Trelegy?
Same device, escalating therapy: Incruse is umeclidinium alone (LAMA); Anoro adds vilanterol (LAMA+LABA); Trelegy adds an inhaled steroid on top (LAMA+LABA+ICS). Which you need is a clinical decision — but each has different pricing and different Medicare-negotiation timelines, so a step-up also changes your cost strategy. We re-run the program comparison whenever your prescription changes.
What If My Application Is Denied?
Denials are usually about documentation — missing income proof, the Medicare $600-spend evidence, or incomplete prescriber sections. Applications can be corrected and resubmitted — and the $35 cap and $159.20 direct price mean nobody goes without while an appeal runs. We review the denial letter, fix what triggered it, and resubmit on your behalf.
Take Control of Your Medication Costs
Free drug at 300% of poverty, a $35 cap, a $159 direct price, and a Part D pathway after $600 spent — Incruse has more affordability routes than almost any inhaler, and the right one depends on your exact situation. Check your eligibility today; the pre-qualification review is free, and if we can’t help you, you pay nothing.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.